Abstracts tagged "Infection and reactive arthritis"

Abstract Number: 947 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcome after Treatment of a National Cohort of PCR-Positive Lyme Arthritis
Marc Scherlinger^1,2, Antoine Grillon³, Jean Sibilia⁴, Benoit Jaulhac³ and Laurent Arnaud^4,5, ¹Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, ²Rheumatology, UMR CNRS 5164 - Immunoconcept, France, Bordeaux, France, ³Centre national de référence Borrelia, CHU de Strasbourg, Strasbourg, France, ⁴Université de Strasbourg, Strasbourg, France, ⁵Service de rhumatologie, CHU de Strasbourg, Strasbourg, France
Background/Purpose: Lyme arthritis (LA) is a disseminated Borrelia infection whom prevalence is lower in Europe than in the USA, probably because of difference in Borrelia…
Abstract Number: 1309 • 2016 ACR/ARHP Annual Meeting
The Incidence of Sexually Acquired Reactive Arthritis: A Systematic Literature Review
Hayley Denison¹, Elizabeth Curtis², Michael Clynes², Collette Bromhead³, Elaine Dennison^2,4 and Rebecca Grainger⁵, ¹School of Biological Sciences, Victoria University of Wellington, Welington, New Zealand, ²MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ³Massey Institute of Food Science and Technology, Massey University, Wellington, New Zealand, ⁴School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand, ⁵University of Otago Wellington, Wellington, New Zealand
Background/Purpose: Reactive Arthritis (ReA) is an inflammatory spondyloarthritis occurring after infection at a distant site. Chlamydia trachomatis is proposed to be the most common cause…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].